Drug Profile
Research programme: companion diagnostics - cancer - ImmunoGen/Ventana Medical Systems
Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen; Ventana Medical Systems
- Developer ImmunoGen; Roche Tissue Diagnostics
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 24 Jul 2023 Discontinued - Preclinical for Cancer (Diagnosis) in USA (unspecified route)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA